Design and implementation of the first randomized controlled trial of coenzyme Q10 in children with primary mitochondrial diseases

Mitochondrion

Volumn 12, Issue 6, 2012, Pages 623-629

  Stacpoole, Peter W ^a   deGrauw, Ton J ^b,e   Feigenbaum, Annette S ^c,f   Hoppel, Charles ^d   Kerr, Douglas S ^d   McCandless, Shawn E ^d   Miles, Michael V ^b   Robinson, Brian H ^c   Tang, Peter H ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Children's Healthcare of Atlanta ^*  (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Clinical trials; Coenzyme Q10; Mitochondrial disease; Respiratory chain

Indexed keywords

MITOCHONDRIAL DNA; PLACEBO; UBIDECARENONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CHILD CARE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL EVALUATION; COMMON COLD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENERGY METABOLISM; FATIGUE; GENE MUTATION; HUMAN; KEARNS SAYRE SYNDROME; LEIGH DISEASE; MAJOR CLINICAL STUDY; MELAS SYNDROME; MENTAL HEALTH; MITOCHONDRIAL RESPIRATION; MULTICENTER STUDY; MUSCLE WEAKNESS; NARP SYNDROME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; STUDY DESIGN; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; HUMANS; MITOCHONDRIAL DISEASES; RESEARCH DESIGN; UBIQUINONE;

EID: 84869083946     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2012.09.005     Document Type: Article

References (37)

1. Arogov Z., Bank W.J., Maris J., et al. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann. Neurol. 1986, 19:598.
2. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:120-131.
3. Bergamini C., Moruzzi N., Sblendido A., Lenaz G., Fato R. A water soluble CoQ10 formulation improves intravellular distribution and promotes mitochondrial respiration in cultured cells. PLoS One 2012, 7:e33712.
4. Bernier F.P., Boneh A., Dennett X., Chow C.W., Cleary M.A., Thorburn D.R. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002, 12:1406-1411.
5. Diogo L., Cordeiro M., Garcia P., Fineza I., Moura C., Oliveira C.R., Veiga M., Garcia T., Grazina M. Value of brain magnetic resonance imaging in mitochondrial respiratory chain disorders. Pediatr. Neurol. 2010, 42:196-200.
6. Duncan A.J., Heales S.J.R., Mills K., Eaton S., Land J.M., Hargreaves I.P. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin. Chem. 2005, 51:2380-2382.
7. Enns G.M., Kinsman S.L., Perlman S.L., Spicer K.M., Abdenur J.E., Cohen B.H., Arnagala A., Barnes A., Kheifets V., Shrader W.D., Thoolen M., Blankenberg F., Miller G. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol. Genet. Metab. 2012, 105:91-102.
8. Evans M., Baisley J., Barss S., Guthrie N. A randomized, double-blind trial on the bioavailability of two CoQ10 formulations. J. Funct. Foods 2009, 1:65-73.
9. 10 and idebenone in the therapy of respiratory chain disorders: rationale and comparative benefits. Mol. Genet. Metab. 2002, 77:21-30.
10. Glover E.I., Martin J., Maher A., Thornhill R.E., Moran G.R. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010, 42:739-748.
11. Haas R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 2007, 7S:S136-S145.
12. Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
13. Kang H.C., Kwon J.W., Lee Y.M., Kim H.D., Lee H.J., Hahn S.H. Nonspecific mitochondrial disease with epilepsy in children: diagnostic approaches and epileptic phenotypes. Childs Nerv. Syst. 2007, 23:1301-1307.
14. Kerr D.S. Treatment of mitochondrial electron transport chain disorders, 2010. A review of clinical trials over the past decade. Mol. Genet. Metab. 2010, 99(3):246-255.
15. Lamperti C., Naini A., Hirano M., De Vivo D.C., Bertini E., Servidei S., Valeriani M., Lynch D., Banwell B., Berg M., Dubrovsky T., Chiriboga C., Angelini C., Pegoraro E., DiMauro S. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003, 60:1206-1208.
16. Lundkvist J.A., Jarnlo G.B., Gummesson C., Nordmark E. Longitudinal construct validity of the GMFM-88 total score and goal total score and the GMGM-66 score in a 5-year follow-up study. Phys. Ther. 2009, 89:342-350.
17. Mancuso M., Orsucci D., Volpi L., Calsolaro V., Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets 2010, 11(1):111-121.
18. Miles M.C., Horn P., Miles L., Tang P., Steele P., DeGrauw T. Bioequivalence of coenzyme Q10 from OTC supplements. Nutr. Res. 2002, 22(8):919-929.
19. Miles M.V., Patterson B.J., Schapiro M.B., Hickey F.J., Chalfonte-Evans M., Horn P.S., Hotze S.L. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr. Neurol. 2006, 35:30-37.
20. Miles M.V., Miles L., Tang P.H., Horn P.S., Steele P.E., DeGrauw A.J., Wong B.L., Bove K.E. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion 2008, 8:170-180.
21. Munnich A., Rotig A., Cormier V., Rustin P. Clinical presentation of respiratory chain deficiency. Metabolic and Molecular Bases of Inherited Disease 2001, 2261-2271. Mc-Graw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
22. Musumeci O., Naini A., Slonim A.E., Skavin N., Hadjigeorgiou G.L., Krawiecki N., Weissman B.M., Tsao C.Y., Mendell J.R., Shanske S., De Vivo D.C., Hirano M., DiMauro S. Familial cerebellar ataxia with muscle Q10 deficiency. Neurology 2001, 56:849-855.
23. Ogasahara S., Engel A.G., Frens D., Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalopathy. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2379-2382.
24. Rahman S., Hargreaves I., Clayton P., Heales S. Neonatal presentation of coenzyme Q10 deficiency. J. Pediatr. 2001, 139:456-458.
25. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tamopolsky M.A. Beneficial effects of creatine, CoQ10 and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35:235-242.
26. Russell D.J., Rosenbaum P.L., Cadman D.T., Gowland C., Hardy S., Jarvis S. The Gross Motor Function Measure: a means to evaluate the effects of physical therapy. Dev. Med. Child Neurol. 1989, 31:341-352.
27. Sacconi S., Trevisson E., Salviati L., Aymé Rigal O., Redondo A.G., Mancuso M., Siciliano G., Tonin P., Angelini C., Auré K., Lombès Desnuelle C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul. Disord. 2010, 20:44-48.
28. 10 in early Parkinson disease. Evidence of slowing of the functional decline. Arch. Neurol. 2002, 59:1541-1550.
29. Stacpoole P.W. Why are there no proven therapies for genetic mitochondrial diseases?. Mitochondrion 2011, 11(5):679-685.
30. Stacpoole P.W. Why are there no proven therapies for genetic mitochondrial diseases. Society for Inherited Metabolic Disorders Annual Meeting, Asilomar, CA, February 28-March 3 2011.
31. Stacpoole P.W. Forward Together! Joining researchers and community in advancing clinical trials for mitochondrial diseases. United Mitochondrial Disease Foundation Annual Symposium Chicago, IL, June 15-19 2011.
32. Stacpoole P.W., Kerr D.S., Barnes C., Bunch S.T., Carney P.R., Fennell E.M., Felitsyn N.M., Rl Gilmore, Greer M., Henderson G.H., Hutson A.D., Neiberger R.E., O'Brien R.G., Perkins L.A., Quisling R.G., Shroads A.L., Shuster J.J., Silverstein J.H., Theriaque D.W., Valenstein E. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006, 117:1519-1531.
33. Stamelou M., Reuss A., Pilatus U., Magerkurth J., Niklowitz P., Eggert K.M., Krisp A., Menke T., Schade-Brittinger C., Oertel W.H., Höglinger G.U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov. Disord. 2008, 23(7):942-949.
34. Tang P.H., Miles M.V., DeGrauw A., Hershey A., Pesce A. HPLC analysis of reduced and oxidized coenzyme Q(10) in human plasma. Clin. Chem. 2001, 47(2):256-265.
35. Turunen M., Olsson, Dallner G. Metabolism and function of coenzyme Q. Biochim. Biophys. Acta 2004, 1660:171-199.
36. Vockley J., Vockley C.M. Clinical trials: curing a critical deficiency in metabolic medicine. Mol. Genet. Metab. 2010, 99(3):244-245.
37. Wolf N.I., Smeitink J.A.M. Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology 2002, 59:1402-1405.